Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axid AR cleared by FDA on May 9; Whitehall touting 30-minute onset of action.

This article was originally published in The Tan Sheet

Executive Summary

WHITEHALL-ROBINS' AXID AR 30-MINUTE ONSET OF ACTION in preventing heartburn is being emphasized by the company in press materials announcing FDA approval of the Rx-to-OTC switch product. The agency cleared the application for nizatidine 75 mg on May 9. The fourth OTC H2 antagonist to receive FDA switch clearance, Axid AR is indicated for the prevention of heartburn, acid indigestion and sour stomach.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel